1. Introduction
The challenging environment of post-marketing monitoring of vaccines in Europe
The influenza pandemic in 2009 highlighted the limited capacity to rapidly collect post-marketing data on the pandemic vaccine exposure, safety and effectiveness in Europe, which was needed to provide a robust and timely benefit/risk assessment [1, 2] . The absence of a formally-established European infrastructure providing access to large data sources, and the lack of collaboration between stakeholders and common methods for data collection were recognised as major limiting factors for the timely collection, analysis and reporting of available data, for benefit and risk assessments [1, 2] . Additional limiting factors such as lack of funding mechanisms and communication channels, compliance with regulatory requirements resting on vaccine marketing authorisation holders (MAHs), while most of the data resided with public health institutes (PHIs), and lack of public trust were identified [3] .
ADVANCE project and best practice guidance
In 2013 the Innovative Medicines Initiative (IMI), funded a consortium of more than 47 public and private partners, the Accelerated Development of VAccine benefit-risk Collaboration in Europe, (ADVANCE) for a five-year period [4] [5] [6] (See Appendix A for list of ADVANCE partners). The aim of this consortium is to implement an efficient, trustworthy framework with transparent governance rules for collecting valid and timely post-marketing data supporting vaccine benefit-risk monitoring, while respecting stakeholders' mandates and enabling each of them to make informed decisions [7] . The ADVANCE consortium, composed of European public and private stakeholders, including national PHIs, the European Centre for Disease Prevention and Control (ECDC), the European Medicines Agency (EMA), national RAs, research institutes, universities, contract research organisations (CROs), and vaccine MAHs, was a unique forum for stakeholders to establish common rules for future public-private collaborations (PPCs).
ADVANCE has developed two components of best practice guidance: a code of conduct for collaborative vaccine benefit-risk studies and governance guidance for transparent, ethical and trustworthy PPCs. Please refer to Appendix B for definitions of the terms PPC, governance, study and project, as used in this paper. The published ADVANCE code of conduct is a set of good practice principles for individuals working in organisations collaborating to perform vaccine studies [8] . The ADVANCE governance guidance summarised in this paper is complementary to the ADVANCE code of conduct and the ENCePP guidelines for pharmacoepidemiological and pharmacovigilance studies as it intends to provide a set of governance proposals for stakeholders wanting to establish transparent, ethical and trustworthy PPCs to perform vaccine benefit-risk studies [8, 9] . As studies carried out within PPCs may be partially supported by diverse stakeholders (through funding or in-kind contributions), good governance principles should ensure that the research is not influenced by commercial, financial, personal or institutional interests of study funders where there is a potential to threaten scientific independence.
Methods
The overall methods used for the development of the governance guidance proposal are summarised in Fig. 1 . The process was initiated in March 2014 and the proposal for guidance was finalised in September 2017.
Landscape analysis via stakeholder survey and literature review
The first step was a landscape analysis through a survey of European stakeholders and a literature review to identify existing PPCs in the field of public health, and more specifically in the vaccine area. It is important to understand that the aim of the landscape analyses was not to perform an exhaustive search, as is required for systematic reviews of evidence for treatment or pharmacoepidemiology, but to identify what type of governance structures other public-private collaborative partnerships use. A more detailed description of the landscape analyses and results can be found in Supplement Online Information.
Briefly, a questionnaire, with 19 open-ended questions, was sent by email to the members of the ADVANCE consortium and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) to collect information about the PPCs they were involved in, including types of interaction, governance, structural funding and lessons learnt (Appendix C). A total of 48 organisations were contacted; 27 responded. Information on 40 collaborations was collected. The responses to the survey provided useful information on the potential added-value of PPCs as well as the challenges and lessons learnt for possible improvements. They highlighted the need for governance guidelines that are adaptable to project specificities.
A PubMed search for vaccine post-marketing collaborative studies published between 1 January 2013 and 19 May 2014, using the keywords [partner* OR collaborat* OR working* OR network*] AND [vaccine*] identified 30 additional collaborations (i.e., described a collaboration in the acknowledgement or disclaimer section) among the 1155 publications that were initially screened. Among the 70 collaborations identified, 38 (54%) were between public and private stakeholders and 32 (46%) between public stakeholders only. We observed high diversity in terminology, in the governance models applied and in the distribution of roles and responsibilities, interactions and funding mechanism between the different stakeholders. In parallel, a non-systematic Google Internet search for available governance guidelines on PPCs revealed that explicitly formalised governance structures are used mainly by large multinational organisations such as the Global Fund, the IMI or GAVI [10] [11] [12] . No clear guidelines were identified at a project level, a project being defined as a set of activities put in place to organise one or several studies (see Appendix B).
Development of the governance framework
In the second step, a working group comprising the authors of this paper, developed the following aspects of a governance framework, using information from the PPCs identified in the landscape analyses: identification of potential advantages and disadvantages of PPCs in the vaccine area; clarification of governance functions; establishment of core principles at the project level to guide the implementation of efficient, transparent and trustworthy PPCs in the European vaccine post-marketing setting. Scenarios frequently encountered by the co-authors (taking into account their different real-life research questions and contexts) were used to explore the potential added-value and challenges of PPCs and to describe the possible functions, roles and responsibilities of the different stakeholders in a PPC and the prerequisites for governance bodies.
Internal and external consultations
In the third step, the working group sought internal input from other members of the ADVANCE consortium and external input from a review panel of independent experts appointed by the ECDC. This panel pointed out that an important challenge for setting up PPCs in the vaccine post-marketing setting was the divergent attitudes to PPCs (expected added-value and governance model), even within the same group of stakeholders in Europe, particularly between PHIs. Therefore, a 2-day workshop was organised in March 2017 at the EMA to seek input about our governance analysis and proposals from a broader group of stakeholders. The participants invited to the workshop were experts involved in or interested in vaccine benefit/risk monitoring in Europe or in the development of public-private interactions proposed by members of the ADVANCE consortium. The aim was to have representatives of different stakeholders, such as public health institutes (scientists with infectious disease expertise from at least 10 European countries), regulatory authorities (from at least 5 different countries), academics, contract research organisations (CROs) (from at least 10 different organisation), at least 5 representatives from patient associations and healthcare organisations and at least 5 lawyers from different participating organisations. The workshop was attended by almost 70 experts representing various stakeholders. There were 14 participants from national public health institutes and the ECDC, 8 from national regulatory authorities and the EMA, 20 from academic institutions and CROs, 16 from vaccine marketing authorisation holders (MAHs), and 8 from patients' associations and health organisations. The countries represented were Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland and UK.
The initial workshop assumption was that, in some circumstances, there is a need for PPCs which have an added-value for vaccine post-marketing projects with shared interests, and the workshop discussed the question of how this need can be addressed. The workshop participants confirmed the need to establish a clear, transparent governance framework that is understandable and accepted by the vaccine scientific community, as well as applicable to the European context for PPCs responsible for vaccine post-marketing projects. Importantly, the attendees emphasised that the level of acceptability of such sensitive interaction and the acceptance of the governance proposals might not be the same for all stakeholders or for all countries. The legal experts present agreed that there are no legal restrictions for developing PPCs for vaccine post-marketing projects at the European level, although there may be legal or institutional constraints that could restrict implementation of PPCs in some European countries. The positive effect of having trust between participating stakeholders within a PPC and between participating and non-participating stakeholders on innovative outcomes and the overall performance of such projects was discussed. A fully transparent process, based on open communication, information-sharing and shared decision-making can increase support for PPCs. Consistent, timely and proactive communication is primordial to help build public trust. The full workshop report is available on the ADVANCE website [13] . Based on the discussions held during the workshop, we adapted our governance framework to a generic model with options to enable adjustments to take into consideration the context and project specificities.
ADVANCE proposals and recommendations
Based on input from reviewers and workshop participants a set of governance proposals and recommendations were made.
Potential advantages and disadvantages of PPCs
In this section, we summarise the discussions held within ADVANCE about the potential advantages and disadvantages of PPCs perceived by the participants, which help to shape the governance proposals. Bringing together the expertise and knowledge of the various stakeholders and the complementarity and resource sharing could be major benefits gained through a PPC ( Fig. 2 ; Appendix D). Multi-stakeholder collaborations that can create scientific, resource and communication synergies may have a greater impact for benefit-risk monitoring than a single stakeholder and could provide more robust results covering diverse populations and larger specific population groups than a single stakeholder. Established PPCs would be more rapidly able to respond to an emergency as the creation of such collaborations can take a considerable time.
One of the major disadvantages of PPCs was found to be the potentially increased complexity and administrative burden due to the need to satisfy the various mandates and obligations of the different stakeholders. MAHs may have to observe stricter obligations than others, for example in terms of time-consuming and resource-intensive traceability and documentation processes. Concerns about scientific integrity and independence due to potential or real conflicts of interest when public authorities and vaccine MAHs collaborate could also have a negative impact on public trust. Undue influence from any of the PPC partners could affect the validity of the results since vaccine post-marketing projects frequently use observational study designs with data that have been collected for other purposes which are more susceptible to bias compared with randomised clinical trial designs, which may result in lower internal validity and raise doubts about the findings. This emphasises the need to acknowledge and carefully consider the risks associated with real or perceived potential conflicts of interest.
Potential partners should discuss the advantages and disadvantages of a PPC for a given project in a transparent manner in order to decide if a PPC is the desirable form of collaboration. We propose that stakeholders should consider PPCs as a mean of facilitating scientific exchange and discussions with the aim of performing high quality studies and obtaining robust scientific evidence, due to the complementarity of the partners and the federation of resources. We recommend, therefore, that PPCs should only be envisaged if the anticipated advantages of the collaboration outweigh the expected disadvantages for all the stakeholders involved. A plan to mitigate any disadvantages arising from the PPC could be developed when the collaboration is initiated.
Core governance principles and functions
We recommend that the following guiding principles are implemented for project governance.
Core governance principles
The governance model should be as simple as possible, transparent, acceptable to all partners, and appropriately-sized to ensure efficiency. The roles and responsibilities and decisionmaking rules should be agreed between the partner organisations and included in the project contract. The structure and processes of the governance model should reflect mutual respect and shared benefits. The governance structure should ensure that the perspectives of all partners will be taken into consideration during the collaboration.
The decision-making process should reflect a fair balance of these perspectives. All decisions, key communication and minutes from governance committee meetings should be recorded to facilitate compliance monitoring. Relevant documents should be made publically available on the project website. A communication plan should be developed and agreed between partners at project initiation.
Participating organisations should develop and promote the scientific autonomy of their employees and reflect this in their internal governance policies and processes. Procedures related to compliance with good practices should be shared between partners and specific training to promote compliance with these should be provided. The same principles defined in the ADVANCE should be applied to the study CoC) [8] .
Core governance functions
We identified five fundamental functions that can be attributed to individual partner organisations or to a governance body or committee with representatives from more than one partner organisation ( Fig. 3 ; Table 1 ; Appendix E). The roles and responsibilities of each organisation will be defined by the functions they assume in the structure.
The decision-making function will require leadership for the strategic direction, allocation of funds and resources and all decision-making related to the project. The scientific advice function will involve making recommendations on the scientific, methodological and ethical aspects of the project and studies. All documents related to the studies performed within the PPC should be submitted for ethics committee approval in compliance with local regulations. The quality control & audit function will involve responsibility for quality control and audit of the studies and will provide advice on the governance. The implementation and management function will involve the implementation and execution of the project and studies, and the financial management function will manage the project funds. Both of these functions will receive guidance from the decision-making function.
The scientific advice functions and the quality control & audit functions are pivotal for guaranteeing scientific relevance, acceptability, ethics and transparency and therefore they must be independent from the decision-making and implementation and management functions. The decision-making function should record how advice and recommendations received from these two advisory functions have been taken into consideration.
It is important to consider that some functions could be merged and be under the responsibility of one or more partner organisations depending on the rationale, scope and objective of the project. For example, if there is a single study planned in a given project, the implementation and management function could be merged with the decision making function. 
Generic model and recommendations for governance
Our internal discussions and external consultations have led us to propose a generic governance model, with options, as an optimal and flexible solution that could take into consideration the wide range of project specificities that may be present in the vaccine post-marketing setting in Europe. Here, we summarise the recommendations for the roles the various partners can play in PPCs (Fig. 4, Table 1 ).
3.3.1. Governance bodies 3.3.1.1. Decision maker or steering committee. The decision-making function can be attributed to a single partner (the decision maker) or to two or more partners as a shared decision-making body (the steering committee) ( Table 1 ). Diverse models for decision-making could be possible, including delegation of defined responsibilities. Rules should be established and agreed by the participating partners when the PPC is being set-up. The decision maker or steering committee should be responsible for selecting members of the scientific and the quality control & audit committees, using a transparent and documented process allowing the selection process to be verified.
3.3.1.2. Scientific committee. This committee will provide scientific, methodological and ethical advice and written recommendations for the project to the decision-making body and for the studies to the implementer or study teams. They will not be responsible for the ethical review of study protocols; these will be reviewed by regular ethics committees in compliance with local regulations. How their recommendations are taken into consideration and, if applicable, the reason(s) why they have not been implemented should be documented.
3.3.1.3. Quality control & audit committee. This committee should be set up at an early stage to enable it to assess, manage and mitigate potential conflicts of interest and provide advice for the selection of the members of the scientific committee. This committee should provide quality control and audit reports, compliance advice and written recommendations for the project to the decision-making body and for the studies to the implementer or study teams. How their recommendations are taken into consideration and, if applicable, the reason(s) why they have not been implemented should be documented.
3.3.1.4. Implementer. The implementation and management function could be attributed to one partner (the implementer) with in-house expertise and resources to assume this function, with the study team members selected in-house. Alternatively, one partner could coordinate the various activities or studies to be conducted by several partners and the study team members could be selected from more than one partner.
3.3.1.5. Financial administrator. When PHIs and vaccine MAHs are involved in the PPC or when more than one funder or countries are involved, a financial administrator should be appointed to manage the funds. The decision maker will be responsible for appointing the financial administrator, after consulting all partners. In all cases, allocation of funds should be transparent and funding sources always clearly identified.
Decision-making rules
At the start of the PPC, the partners should agree what decisionmaking process will be used to ensure achievement of the objectives. Consensus for decision-making is strongly recommended since this will encourage partners to seek an agreement that incorporates all points of view. However, we recommend that there is a back-up option with a majority-voting process when consensual decisions cannot be reached to ensure that the project goes ahead. If this option is selected, before PPC initiation, the partners should decide on the quorum of members to be present or represented (e.g. two-thirds), and what would constitute a majority vote (e.g. >50%, >75%). Discordant viewpoints should be recorded with the final decision or deliverable. When decisions cannot be reached or when major issues, concerns or objections are raised, advice should be sought internally from the project advisory bodies (scientific committee and quality control and audit committee) or externally from other experts and non-partner organisations. 
Patient associations and civil society organisations
The active participation of patient associations and civil society organisations is strongly recommended because of their addedvalue for a productive vaccine post-marketing benefit-risk evaluation, as well as for their support for enhancing transparency and public trust. They could be involved as members of the steering committee (with voting rights or as observers), or as members of the scientific committee or quality control & audit committee for those with the relevant expertise. They could also be involved as independent external experts, e.g., for reviewing project information in external communication material for the lay public.
Management plan for conflicts of interest
All actors involved in PPCs can have potential conflicts of interests (CoIs) which can be financial or non-financial (e.g. professional interests, personal or family relationships, commercial or academic competition, beliefs). Since vaccine MAHs have specific, large commercial interests, their roles in PPCs should be clearly defined and completely transparent as indicated in Table 1 . The impact of the CoIs on the governance functions should be evaluated at both individual and organisational levels, using a transparent CoI management plan implemented at project initiation, under the responsibility of the quality control and audit committee. As recommended in several guidelines, e.g. WHO, EMA, OECD, the constructive management of CoIs should focus on identifying and mitigating the related risk on the project rather than systematically excluding stakeholders with potential CoIs [14] [15] [16] . Despite this, in some instances, CoIs may lead to exclusion of individual experts or organisations for some decision-making or governance functions that may be unduly affected by the consequence of these CoIs. However, they do not have to be excluded from the whole project since they may assume other functions within the PPC that are not impacted by their CoIs. Alternatively, a shared decisionmaking body composed of stakeholders with different interests (e.g. academic, commercial, public health, regulatory) could be envisaged. This could avoid undue influence by a specific stakeholder and dilute any potential negative impact from CoIs. The same approach could be used for the study team (in compliance with the ADVANCE CoC) [8] .
Contractual considerations for PPCs
A single contract should be signed by all partners to avoid multiple bi-partner or heterogeneous contracts and to improve transparency. The contract should clearly define the project objectives, the rational of the collaboration, the role, obligations, rights and responsibilities of each partner, the financial terms, the confidentiality rules, the data protection rules, CoI management rules, ethical considerations and other general information, such as the dates of the project start and end, termination terms etc. Dissemination and publication plans for the results should be described in the contract. The ownership and rights for usage of results from the PPC should be discussed on a case-by-case basis and the decision rules clearly defined in the contract. In all cases, publications should comply with international guidance, such as the recommendations from the International Committee of Medical Journal Editors (ICMJE) [17] .
The objective of this guidance is to make the process for starting a project more efficient by providing governance structure and guidelines. Since the complexity of the research question, the number of partners and the project duration and settings will vary, it is very difficult to provide a range of timelines. Real-life collaborations in the future should help by providing some estimates of the project duration.
Discussion and conclusions
In this article we have described a set of governance proposals (functions, core principles and generic model) and recommendations aiming to support stakeholders willing and able to develop European PPCs in a post-marketing setting for vaccines. Together with the ADVANCE code of conduct, these governance proposals are expected to generate a favourable environment for the conduct of trustworthy, valid studies, which will also satisfy the ENCePP guidelines and criteria on quality, transparency and scientific integrity. At the European level, collaborative vaccine postmarketing projects taking into consideration unmet medical needs for vaccines, regulatory requirements and PHIs' priorities are hampered by the current context of vaccine hesitancy and public distrust in institutions. In this light, ADVANCE has developed guidance for appropriate communication strategies for vaccine benefit/risk results produced by PPCs . The discussion about methods initiated in ADVANCE needs to be continued to address the specificities of vaccine-preventable diseases and to involve all stakeholders with the participation of the main European institutions, i.e., the ECDC and the EMA.
The IMI is a PPC between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) which was launched in 2008 [5, 18, 19] . In the 10 years of their existence, they have financed almost 100 collaborative projects, mainly focused on early phases of drug and vaccine development. These successful projects have highlighted how collaborations can accelerate important innovations in medical research and drug development in Europe [20] .
While our ADVANCE European governance model is based on existing high-level principles which can be found, for example, in the GAVI and Global Fund models, to our knowledge, there are no other governance frameworks or recommendations to date that are directly applicable to the setting of vaccine post-marketing benefit/risk assessment. Nevertheless, the proposed framework can be readily adapted to other scientific settings or regions in the world.
We conclude that in vaccine post-marketing settings there is no one-size-fits-all solution for governance of PPCs. The governance structure should be transparent and flexible, avoiding unnecessary complexity, to ensure that the project objectives are achieved, i.e., delivery of evidence on vaccines and vaccination programs to enable informed decision-making which will contribute to improved public health. We acknowledge that a PPC will not be suitable for all projects and that collaboration between public and private partners may be viewed with scepticism by some, particularly if CoIs are not managed properly. These proposals for governance guidance now need to be applied in real-life collaborations (e.g. one potential collaboration is the DRIVE project, also funded by the IMI) to assess what works and what does not work and what added-value can be obtained from these collaborations.
Prior presentations
Oral presentation at the International Society of Vaccines congress in Paris 5-7 October 2017 entitled: ADVANCE governance framework for public-private collaborations: Towards strengthening vaccine benefit-risk monitoring in Europe.
Oral 
Appendix B

B.1. Definitions
Private-public collaboration (PPC): an engagement of public and private organisations, who share common interests in vaccine benefit-risk monitoring, to work together in a project. The roles and responsibilities of each partner organisation are agreed and formalised through a contract agreement. This could be a shortterm (study-specific) or a long-term broader project.
Governance: processes of interaction and decision-making among the stakeholders involved in a PPC.
Study: investigation carried-out to answer a well-defined research question on vaccine benefit-risk monitoring in postmarketing settings.
Project: set of activities to organise one or several studies or other long-term activities (such as database network or multiyear vaccine monitoring) designed to address vaccine benefit-risk monitoring in post-marketing settings. How confidentiality was respected Transparency:
How transparency was respected (registration on public website/ publication etc.) Funding:
Name of the funders and how the budget has been shared (equal parts, proportional to data etc.) Scientific independence:
How independence from funding sources was respected (ownership of results, data property and sharing, publication rules, etc.) Countries:
Countries which were data sources Duration/time period:
When the model was created, is it planned to be repeated/extended Case study details:
Was the model was focussed on one case study ; could it be extended to several case studies Regulatory/ethical reviews:
Which regulatory process, applicable law, compliance rules and ethical reviews were applied to the model and/ or the case study (commitment, scientific committee, referential like ENCePP ..) What went well:
Perceived successes Which difficulty was encountered:
Perceived issues (solved or not)
What should be improved:
Areas for improvements
Comments:
Add any additional information which may be relevant for the model description
